1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Xvivo Perfusion AB (publ)

Xvivo Perfusion AB (publ)

XVIPF
Xvivo Perfusion AB (publ)US flagOther OTC
29.39
USD
- -
- -
925.77MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
3.52
4.12
5.59
6.12
5.83
7.14
8.33
6.62
8.96
14.07
19.96
26.11
25.78
26.13
Basic EPS, GAAP
0.41
0.25
0.24
0.07
0.25
0.48
0.19
-1.61
0.28
0.62
3.07
5.47
0.8
3.54
Free Cash Flow per Basic Share
0.04
-0.95
-0.22
-0.35
-0.5
-1.18
-2.04
-2.83
-3.68
-3.49
-3.26
-2.6
-4.82
2.49
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.63
0.86
0.98
0.99
1.1
1.54
1.72
0.07
0.35
0.97
4.02
9.29
10.09
8.94
Tangible Book Value per Share
0.38
3.78
4.09
4.11
10.3
9.91
9.01
14.13
12.48
8.53
24.21
23.79
21.05
21.75
Basic Weighted Avg Shares
20
21
22
23
25
26
27
27
29
30
30
31
31
31
Sales/Revenue/Turnover
69
85
120
138
148
188
221
180
258
415
598
822
812
823
Operating Margin (%)
14.9
9.31
6.76
2.41
4.92
7.18
1.8
-24.57
-7.25
1.07
0.9
10.87
11.34
8.46
Depreciation Expense
2
4
12
13
15
17
25
30
32
42
76
88
70
- -
Net Income, GAAP
8
5
5
2
6
13
5
-44
8
18
92
172
25
111
Effective Tax Rate (%)
24.86
30.62
30.64
49.85
16
27.51
6.64
- -
- -
17.42
2.86
13.89
34.74
7.11
Profit Margin (%)
11.69
6.16
4.27
1.09
4.22
6.75
2.24
-24.32
3.15
4.44
15.37
20.94
3.1
13.53
Working Capital
7
75
80
68
234
235
207
391
443
333
692
636
569
612
LT Debt
- -
- -
- -
- -
- -
- -
2
3
2
4
21
23
113
103
Total Equity
97
178
185
316
504
540
578
1,008
1,285
1,430
1,945
2,157
2,113
2,092
Return on Invested Capital (%)
7.48
3.79
3.06
0.66
1.49
1.87
0.66
- -
- -
0.27
0.31
3.68
2.71
3.04
Return on Capital (%)
14.55
29.54
26.83
7.15
25.25
37.23
11.35
- -
- -
69.75
97.7
72.43
7.13
37.75
Return on Common Equity (%)
16.74
34.82
26.47
6.92
24.89
36.96
11.47
-184.54
137.12
95.61
123.34
83.39
8.25
49.27

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
11
9
8
LT Borrowings
- -
- -
- -
LT Finance Leases
23
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
31
31
31
Market Capitalization
14,385
9,526
9,013

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
813
726
773
Cash, Cash Equivalents & STI
416
316
323
Accounts Receivable, Net
117
185
181
Inventories
227
226
269
Total Current Liabilities
178
140
161
Payables & Accruals
- -
- -
- -
ST Debt
11
9
8
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
30.28%
16.72%
-2.01%
Free Cash Flow
49.13%
19.82%
85.48%
Net Income, GAAP
-28.98%
81.56%
-85.39%
Sales/Revenue/Turnover
23.26%
36.93%
-1.25%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
186
210
198
228
822
2025
219
178
226
- -
812
2026
241
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.72
0.86
2.72
1.16
5.47
2025
-0.39
0.05
1
- -
0.8
2026
1.15
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Christoffer Rosenblad
Full Time Employees
193
Sector
Healthcare
Industry
Medical - Devices
Address
MAessans gata 10 Gothenburg Sweden 412 51
IPO Date
Jul 21, 2014
Website
xvivoperfusion.com
Similar Companies
Xylo Technologies Ltd. (MDGS)
Allurion Technologies Inc. (ALUR)
Clinical Laserthermia Systems AB (publ) (CLS-B.ST)
Sensus Healthcare, Inc. (SRTS)
Eiken Chemical Co., Ltd. (4549.T)
Guided Therapeutics, Inc. (GTHP)
Business
XVIVO Perfusion AB (publ) operates as a medical technology innovator, delivering sophisticated solutions for the preservation, assessment, and transport of organs intended for transplantation across diverse global regions including Sweden, the Americas, Europe, the Middle East, Africa, and Asia Pacific. The company develops advanced systems that expand the viability and availability of donor organs, including lungs, hearts, livers, and kidneys. Its offerings encompass comprehensive machine perfusion platforms, such as the XVIVO System, a complete cardiac bypass setup designed for safe ex vivo lung perfusion (EVLP), alongside essential disposable lung kits and specialized buffered solutions like STEEN Solution for isolated donor lung assessment. For static cold storage, they provide Perfadex Plus, an extracellular preservation solution widely adopted in lung transplantation. Additionally, the portfolio extends to perfusion devices for abdominal organs, including Liver Assist for diverse liver perfusion protocols and Kidney Assist Transport for oxygenated kidney preservation, aiming to improve transplant outcomes and logistics. Beyond these systems, the company supplies necessary sterile tubing sets, organ chambers, and cannulas. Complementing its product line, XVIVO also offers organ recovery services, expert perfusionist support, and integrated communication tools for transplant teams. Established in 1998, the company maintains its headquarters in Gothenburg, Sweden.

Company News

APIChat

  • seekingalpha.com

    Xvivo Perfusion AB (publ) (XVIPY) Q1 2026 Earnings Call Transcript